Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000027046
JPRN-UMIN000027046
Not yet recruiting
未知

Aproach to optimize the dose of contrasut medicum considering patient's blood flow on CTA. - contrast medium on CTA

Ryukyu unversity hospital0 sites50 target enrollmentJuly 1, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsnone

Overview

Phase
未知
Intervention
Not specified
Conditions
none
Sponsor
Ryukyu unversity hospital
Enrollment
50
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ryukyu unversity hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\.Case of constraction of the adamkiewicz artery 2\.Case of ECG gating 3\.Case of deteriorated images due to fail in hold bless 4\.Case of emergence

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Pharmaceutical guidance for optimizing the use of asthma medications
RBR-9kkjvnjniversidade Federal do Rio Grande do Norte
Suspended
Not Applicable
Optimization of the pharmacological component using additive placeboeffects: Is it possible to enhance the psychological component during self-medication by disclosing information about the psychological componentsself-medication: participants using a specific analgesic (ibuprofen, paracetamol, aspirin) for pain relief self-medication: participants using a specific antihistamine (dimetindene, loratadine, cetirizine) for itch relief
DRKS00009506niversitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie108
Completed
Not Applicable
Pharmacists' review of medicine during admission to hospitalIn-hospital adverse drug eventsNot ApplicableOther complications of surgical and medical care, not elsewhere classified
ISRCTN08043800Region Zealand Hospital Pharmacy (Region Sjaelland Sygehusapoteket) (Denmark)648
Not yet recruiting
Phase 2
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and /​ or MSI mCRC. (NIPISAFE)
2024-518138-10-00Association Gercor93
Completed
Not Applicable
Development of a method for better estimation of warfarin dose in patients requiring warfarin therapyHealth Condition 1: null- atrial fibrillation and valve replacement patients requiring chronic anticoagulation therapy
CTRI/2018/06/014614Dr Nusrat Shafiq82